drugset / Trial / NCT07267559

Dual Orexin Antagonism and Emotion and Affective Processing Study

NCT07267559

Phase 4 Recruiting 62 enrolled University of Oxford
RandomizedParallel-groupTriple-blindOther

Summary

In this study, the investigators will examine the effects of blocking the orexin system on human behaviour and brain function using daridorexant, a medication that inhibits orexin activity. Orexin is a brain chemical involved in regulating sleep, emotion, motivation, and stress responses, which are often disrupted in mental health disorders. Healthy volunteers will be randomly assigned to receive a single dose of daridorexant or placebo in a double-blind design. Participants will then complete behavioural and cognitive tasks assessing emotional processing, aversive learning, and executive function. The study aims to clarify the role of orexin in emotional and cognitive processes relevant to conditions such as depression and anxiety.

Timeline

Start
2025-10-01
Primary completion
2026-09-01
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral

Indications